Wang Xueshun, Huang Boshi, Suzuki Takayoshi, Liu Xinyong, Zhan Peng
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, PR China.
Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-Cho, Sakyo-Ku, Kyoto 606-0823, Japan.
Epigenomics. 2015;7(8):1379-96. doi: 10.2217/epi.15.86. Epub 2015 Dec 8.
LSD1 is an epigenetic modulator associated with transcriptional regulation of genes involved in a broad spectrum of key cellular processes, and its activity is often altered under pathological conditions. LSD1 inhibitors are considered to be candidates for therapy of cancer, viral diseases and neurodegeneration. Many LSD1 inhibitors with various scaffolds have been disclosed, and a few potent molecules are in different stages of clinical development. In this review, we summarize recent biological findings on the roles of LSD1 and the current understanding of the clinical significance of LSD1, and focus on the medicinal chemistry strategies used in the design and development of LSD1 inhibitors as drug-like epigenetic modulators since 2012, including a brief consideration of structure-activity relationships.
赖氨酸特异性去甲基化酶1(LSD1)是一种表观遗传调节剂,与参与广泛关键细胞过程的基因转录调控相关,其活性在病理条件下常发生改变。LSD1抑制剂被认为是癌症、病毒性疾病和神经退行性疾病治疗的候选药物。已经披露了许多具有各种骨架的LSD1抑制剂,一些强效分子正处于不同阶段的临床开发中。在本综述中,我们总结了关于LSD1作用的最新生物学发现以及对LSD1临床意义的当前认识,并重点关注自2012年以来用于设计和开发作为类药物表观遗传调节剂的LSD1抑制剂的药物化学策略,包括对构效关系的简要考虑。